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Abstract
Purpose To describe ophthalmological characteristics of 13
patients with primary hyperaldosteronism (PA).
Methods Cross-sectional study. All patients underwent exten-
sive ophthalmological examination.
Results Thirteen PA patients (9 male, 4 female) were diag-
nosed with arterial hypertension for 11.0 ± 11.2 years.
Ophthalmological imaging revealed macular serous subretinal
fluid (SRF) on optical coherence tomography in 2 patients
(15 %). In one of these patients, bilateral chronic central se-
rous chorioretinopathy (CSC) with polypoidal choroidal
neovasculopathy was diagnosed, which was effectively treat-
ed with full-dose photodynamic therapy. In the other patient
with SRF and bilateral diffuse hyperfluorescent areas on
fluorescein angiography, the SRF had decreased spontaneous-
ly after 6 weeks of follow-up. In 5 of the remaining patients
(38 %), retinal pigment epithelium alterations resembling
findings characteristic for CSC were seen on multimodal im-
aging. The mean subfoveal choroidal thickness was 290.2
± 65.0 μm.
Conclusions Retinal abnormalities resembling (subclinical)
CSC are common in patients with PA. These findings in-
dicate that mineralocorticoid-mediated pathways are in-
volved in the pathogenesis of CSC. In CSC patients with
hypertension of unknown origin, a diagnosis of PA should
be considered.
Keywords Central serous chorioretinopathy . Eplerenone .
Hyperaldosteronism .Mineralocorticoid antagonist .
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Introduction
Central serous chorioretinopathy (CSC) is a chorioretinal
disease, characterized by a neuroretinal detachment due to
the presence of serous subretinal fluid (SRF), as a result
of dysfunction of the retinal pigment epithelium (RPE),
and hyperpermeability and thickening of the underlying
choroid. The exact pathogenetic mechanism of CSC still
has to be unravelled [1–5]. CSC is more common in men,
and presents with complaints such as vision loss, image
distortion, and loss of color and contrast vision [2–4, 6,
7]. Genetic risk factors may play a role in CSC,
possibly via the complement system [8–10]. Exposure to
both endogenous (endogenous hypercortisolism/Cushing’s
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syndrome) and exogenous corticoids is strongly associat-
ed with CSC [11–14]. However, the pathogenetic expla-
nation for the link between CSC and corticosteroids is
currently unclear. In the pathogenesis of CSC, both the
glucocorticoid receptor (GR) and the mineralocorticoid
receptor (MR), a receptor with equal affinity for glucocor-
ticoids and for mineralocorticoids such as aldosterone,
have been postulated to play a role [2].
In a rat model, overstimulation of the MR resulted in cho-
roidal changes resembling findings in CSC patients [15].
Several pilot studies have indicated that there may be a ther-
apeutic role for the MR antagonists spironolactone and
eplerenone in the treatment of CSC [16–19]. However, the
effect of these antagonists on central macular and choroidal
thickness (CT) and on complete and durable resolution of SRF
after cessation of therapy is unclear, and randomized con-
trolled trials are currently lacking [18–20]. Although the in-
creased incidence of CSC in patients with endogenous
hypercortisolism is well-known [14, 21, 22], no studies have
been published on the occurrence of CSC in patients with
primary aldosteronism (PA, primary hyperaldosteronism) thus
far.
PA is characterized by the overproduction of aldoste-
rone by one or both of the adrenal glands, independent of
its normal regulator angiotensin II. Unilateral adrenal ad-
enoma (Conn’s disease) and bilateral adrenal hyperplasia
account for more than 90 % of PA cases. For these dis-
eases laparoscopic adrenalectomy and MR antagonists
such as spironolactone and eplerenone are recommended,
respectively. PA due to both adrenal and non-adrenal al-
dosterone-producing tumors, primary unilateral adrenal
hyperplasia, and familial hyperaldosteronism occurs less
frequently [23].
Although the associat ion between endogenous
hypercortisolism and CSC is well-established [14, 21, 22],
and there may be a role for MR and treatment with MR an-
tagonists in CSC, it is unknown if PA is also associated with
CSC-like abnormalities. Therefore, in this study we examined
patients with PA to detect clinical findings indicative of
(subclinical) CSC.
Methods
Patient selection
In this cross-sectional study, 13 patients with PA were
referred to the Department of Ophthalmology of the
Leiden University Medical Center for ophthalmological
analysis. PA patients in whom diagnosis had been
established between May 2008 and August 2015 were
asked to take part in this study. Both patients who already
received either surgery or medication because of the
hyperaldosteronism and patients who had not received
any PA treatment were included in this study. One patient
with a pituitary adenoma, influencing the hypothalamic-
pituitary-adrenal axis, was excluded because of a known
relationship of this disease with CSC [14, 21, 22]. Written
informed consent for the enrollment was obtained from all
subjects. The study adhered to the tenets of the
Declaration of Helsinki. Approval of the institutional re-
view board and the ethics committee was obtained
(NL50816.058.14).
Ophthalmological imaging
All patients received complete ophthalmic examination,
including Early Treatment of Diabetic Retinopathy Study
(ETDRS) best-corrected visual acuity (BCVA) measure-
ment. After this measurement, pupils were dilated by
using 1 % tropicamide and 5 % phenylephrine. Indirect
ophthalmoscopy and digital color fundus photography
(Topcon Corp., Tokyo, Japan) were performed, and opti-
cal coherence tomography (OCT), enhanced depth imag-
ing (EDI-)OCT, fundus autofluorescence, and oral fluo-
rescein angiography (FA) images were obtained, using
spec t r a l -doma in OCT (Spec t r a l i s HRA + OCT;
Heidelberg Engineering, Dublin, CA, USA). EDI-OCT
was used to measure subfoveal CT. Images were evaluat-
ed by an experienced retina specialist (CJFB). Oral FA
was performed after 10 milliliters of 20 % fluorescein
was administered orally after a fasting period of at least
3 hours, and photos were taken at 10, 15, 20, 25, and
30 minutes after administration. When ophthalmological
imaging revealed findings requiring treatment and/or
follow-up based on the judgment of the treating ophthal-
mologist, these visits were scheduled at our outpatient
clinic. Based on the results of the ophthalmological
screening, indocyanine green angiography using the
spectral-domain OCT could also be performed if deemed
necessary.
Results
Patient characteristics
The mean age of the 13 PA patients (9 male, 4 female) was
55.1 ± 12.0 years (range, 36–74 years). All patients had
arterial hypertension, which is the most prominent clinical
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sign of PA [23]. Hypertension was diagnosed 11.0
± 11.2 years (range, 0.5–43 years) before ophthalmological
evaluation. No significant difference between the patients
with and without ophthalmological abnormalities could be
detected regarding both patient age and duration of pre-
existing hypertension. At the moment of PA presentation,
hypertension was treatment-resistant (need of prescription
of >2 antihypertensive agents) in 8 patients (62 %). At the
time of ophthalmological phenotyping, two patients still
had hypertension despite antihypertensive treatment.
Hypokalemia, a sign of relatively severe PA [24], devel-
oped either spontaneously or after the use of diuretics and
always in combination with hypertension [23], was a pre-
senting symptom of PA in 10 patients (77 %). Obstructive
sleep apnea syndrome was previously diagnosed in one
patient. No other diseases known to be possibly associated
with CSC were present in the included patients.
At the time of the visit to the Department of Ophthalmology,
3 patients were on chronic spironolactone treatment and 3 pa-
tients used eplerenone as antihypertensive treatment, previous-
ly prescribed by the endocrinologist for a mean duration of
2.2 years (range, 10 weeks – 7 years). One patient reported
the current local nasal daily use of the steroid fluticasone, be-
cause of allergic rhinitis. Two other patients reported a previous
short course of oral steroid treatment in 2012 and cutaneous
steroid treatment in 2013, respectively. No patients reported the
use of either sildenafil or tadalafil.
PA due to unilateral adrenal adenoma was diagnosed in
seven patients; bilateral adrenal hyperplasia was detected
in three patients. In one patient, the cause of PA was not
found. Six patients had undergone unilateral laparoscopic
adrenalectomy at the time of the ophthalmological evalu-
ation. Another patient was already scheduled for surgery
and was prescribed eplerenone and nifedipine at the
Table 1 Clinical characteristics of patients with primary hyperaldosteronism (PA)
Patient Age Gender Type (Type
of Surgery)
Systemic Presentation
of PA
Current Medication
1 72 M Adrenal adenoma (−) Hypertension Amlodipine, enalapril, phenprocoumon,
propafenone, spironolactone
2 64 F Unknown origin (−) Therapy-resistant hypertension Colecalciferol/calcium carbonate,
levothyroxine,
metoprolol, spironolactone
3 59 M Adrenal adenoma
(laparoscopic adrenalectomy)
Therapy-resistant hypertension,
hypokalemia
Colecalciferol, doxasozin, furosemide,
nifedipine, omeprazole
4 62 F Adrenal hyperplasia (−) Hypertension, hypokalemia Amlodipine, colecalciferol/calcium carbonate,
melatonin, simvastatin, potassium
chloride, spironolactone
5 42 M Adrenal adenoma (laparoscopic
adrenalectomy)
Therapy-resistant hypertension,
hypokalemia
Amlodipine, calcium carbonate, metoprolol,
perindopril
6 41 M Adrenal adenoma (laparoscopic
adrenalectomy)
Hypertension, hypokalemia Nifedipine
7 50 M Adrenal adenoma (laparoscopic
adrenalectomy)
Therapy-resistant hypertension,
hypokalemia
Barnidipine
8 36 F Adrenal adenoma (laparoscopic
adrenalectomy)
Hypertension, hypokalemia –
9 58 M Adrenal hyperplasia
(laparoscopic
adrenalectomy)
Therapy-resistant hypertension,
hypokalemia
Amlodipine, enalapril
10 74 M Adrenal adenoma (−) Therapy-resistant hypertension,
hypokalemia
Amlodipine, eplerenone, losartan
11 48 M Adrenal hyperplasia
(laparoscopic
adrenalectomy)
Hypertension, hypokalemia Eplerenone, metformin, nifedipine
12 58 M Adrenal hyperplasia (−) Therapy-resistant hypertension,
hypokalemia
Acetylsalicylic acid, barnidipine, diclofenac,
eplerenone, fluticasone, perindopril,
potassium chloride
13 45 F Unknown origin (scheduled
for adrenal vein sampling)
Therapy-resistant hypertension Amlodipine, hydrochlorothiazide
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moment of ophthalmological analysis. After surgery, path-
ological analysis revealed hyperplasia of the excised ad-
renal gland. The last patient was scheduled to receive
adrenal vein sampling to detect the origin of PA. Eleven
out of the other 12 patients were treated with antihyper-
tensive drugs, including the three patients who used
spironolactone and three pat ients who received
eplerenone for this purpose. Clinical characteristics of
the patients are summarized in Table 1.
Ophthalmic characteristics
Ophthalmologic history taking revealed one 64-year-old
female patient who reported unilateral blurred vision and
metamorphopsia. This patient had been visiting another
hospital since 2012 because of ‘early age-related macular
degeneration’. Ophthalmological history revealed that two
other patients had been previously diagnosed with venous
hemi-occlusion, for which scatter laser coagulation treat-
ment was performed. Another patient was previously diag-
nosed with a choroidal naevus. Ophthalmic family history
was unremarkable except for one PA patient who reported
a mother who was previously diagnosed elsewhere with
age-related macular degeneration. Mean ETDRS BCVA
of the 26 eyes was 89.0 ± 6.5 letters (range, 67–99 letters),
with a mean spherical equivalent of the manifest refraction
of 0.19 ± 2.39 diopters (range, −6.25 to +5 diopters).
On OCT, fovea-involving serous SRF was detected in
2 of 13 patients (15 %; a 64-year-old female and a 74-
year-old male patient). Imaging of the female patient, to
whom spironolactone 50 mg thrice daily was being pre-
scribed since 2008, showed signs of bilateral chronic CSC
(Fig. 1a–i, k–l). On FA, hot spots of leakage were detect-
ed in the right eye (Fig. 1e). As part of standard clinical
care, she underwent indocyanine green angiography,
which showed polypoidal choroidal vasculopathy on the
border of an area of a possible occult neovascularisation
(Fig. 1f). The patient was scheduled for full-dose photo-
dynamic therapy, leading to disappearance of SRF at the
evaluation visit 6 weeks later (Fig. 1j). At the follow-up
vis i t 3 months af ter PDT, no SRF was present .
Ophthalmological imaging in the male patient (Fig. 1m–
t, v), who was using eplerenone 100 mg twice daily since
2012 and in whom bilateral diffuse hyperfluorescent areas
were detected on FA (Fig. 1q-r) showed serous SRF
(Fig. 1s). The SRF had decreased at the scheduled visit
6 weeks later (Fig. 1u). OCT imaging revealed outer
photoreceptor/RPE changes reminiscent of changes in
chronic CSC in 5 of the remaining patients (38 %), which
was supported by corresponding hyperfluorescent
changes on FA (Fig. 2a–t). Out of these patients, only 1
patient was using spironolactone since 10 weeks. Fundus
autofluorescence showed variable mild hypo- and
hyperfluorescence of the lesions. The blood pressure of
Fig. 1 Ophthalmological imaging of two patients with primary
hyperaldosteronism in whom foveal subretinal fluid (SRF) was
detected at screening. a–l. Multimodal imaging of a 64-year-old
female with primary hyperaldosteronism. Fundus photography of
the right eye (a) revealed central irregular yellowish changes in
the fovea and milder focal pigmentary changes in the temporal
macula, with multifocal autofluorescence changes on fundus
autofluorescence (FAF; b). Fundus photography of the left eye
(c) also showed mild ret inal pigment epithelium (RPE)
abnormalities, with both hypo- and hyperautofluorescent changes
on FAF temporally in the macula (d). On fluorescein angiography
(FA) of the right eye (e) two hot spots of leakage were present in
the temporal macula, as well as a hyperfluorescent spot inferior to
the fovea. Indocyanine green angiography (ICGA) revealed a le-
sion suspicious for polypoidal choroidal vasculopathy in the right
eye (white arrowhead), possibly on the border of an area of an
occult neovascularisation (white arrow; f). Hyperfluorescent areas
compatible with chronic central serous chorioretinopathy (CSC) on
ICGA of the left eye (h) were larger as compared to the areas on
FA (g). Optical coherence tomography (OCT) revealed foveal SRF
in the right eye (i), with the presence of a round, dome-shaped
RPE detachment (large white arrowhead in i) corresponding to
the small round polyp on ICGA (white arrowhead in f), in associ-
ation with a more shallow RPE detachment (Bdouble layer sign^,
small black arrowhead in i) that may correspond to the possible
occult neovascularisation seen on ICGA (small black arrowhead in
f). Moreover, extrafoveal RPE alterations were found on OCT. At
baseline, subfoveal choroidal thickness (CT) was 235 μm in the
right and 206 μm in the left eye. The patient underwent full-dose
photodynamic therapy in the right eye, refusing anti-vascular en-
dothelial growth factor treatment as an additive treatment. At the
evaluation visit 6 weeks after therapy, the SRF in the right eye (j)
had disappeared, with the RPE detachments still present. No foveal
SRF was present on OCT in the left eye (k; lower scan in g and h).
An extrafoveal OCT of this eye (l; upper scan in g and h) revealed
RPE changes temporally in the macular region. At the evaluation
visit, subfoveal CT in the right eye had decreased to 220 μm. m–v.
Multimodal imaging of a 74-year-old male patient with primary
hyperaldosteronism. Fundus photography of the right eye (m)
showed mild foveal and extrafoveal RPE abnormalities, and mild
irregular peripapillary changes on FAF (n). Fundus photography of
the left eye (o) revealed mainly extrafoveal RPE changes, with the
same picture on FAF (p) as in the right eye. FA of the right (q)
and left eye (r) showed multifocal hyperfluorescent areas. The
foveal OCT scan of the right eye (s) showed shallow serous SRF
and RPE and outer photoreceptor changes suggestive of CSC,
whereas the foveal OCT scan of the left eye was normal.
Extrafoveal OCT scanning in the left eye (t and v; upper and lower
scan in r) showed RPE/outer photoreceptor changes without SRF,
despite the possible hot spot of leakage on FA. At screening,
subfoveal CT was 232 μm in the right eye and 274 μm in the
left. On OCT, foveal SRF in the right eye (u) had decreased
after 6 weeks of follow-up.
2036 Graefes Arch Clin Exp Ophthalmol (2016) 254:2033–2042
one of these patients was not adequately controlled. In the
other hypertensive patient, no ophthalmological patholo-
gy could be detected. Ophthalmological phenotyping of
the three patients who reported current or previous steroid
use did not reveal any abnormalities. In all 13 patients,
mean subfoveal CT on EDI-OCT was 290.2 ± 65.0 μm
(range, 123–377 μm). Ophthalmological characteristics
of the patients are summarized in Table 2.
Discussion
In this study, 7 out of 13 PA patients (54 %) had a
variable degree of outer retinal and RPE changes on
multimodal imaging. Two of these patients (29 %) had
serous SRF leakage in the macula, including a patient
with CSC-like changes and unilateral polypoidal choroi-
dal vasculopathy (Fig. 1a–l), and a patient with
Graefes Arch Clin Exp Ophthalmol (2016) 254:2033–2042 2037
unilateral CSC with subfoveal fluid and bilateral RPE
changes resembling those seen in chronic CSC
(Fig. 1m–v). Despite the fact that the latter patients used
MR antagonists at the time of ophthalmological
2038 Graefes Arch Clin Exp Ophthalmol (2016) 254:2033–2042
evaluation, the abnormalities and serous SRF leakage
were present. In the five other patients, retinal abnor-
malities that could be characteristic of (subclinical) CSC
were seen. Although we observed RPE abnormalities
and no history of SRF in these patients, mean subfoveal
CT at the time of evaluation in the current case series
of PA patients was comparable with the findings in
healthy volunteers [25, 26]. Despite the fact that mean
subfoveal CT in CSC patients is usually increased com-
pared to healthy subjects [27–29], several authors have
described that this is not the case in all CSC patients
[28, 29]. The small number of included patients and the
relatively high age of these possible CSC patients could
also have contributed to the normal subfoveal CT in this
study [30].
Based on the results of this study, aldosterone and the
MR-mediated pathway may play a role in the pathogen-
esis of CSC-l ike changes in pat ients with PA.
Aldosterone and cortisol are adrenal cortical steroid hor-
mones that exert their actions via the MR and GR. It is
unclear how aldosterone and the MR may be linked to
the pathogenesis of CSC. The MR is present in the
choroid, the RPE, and neurosensory retina, as observed
in humans, ra ts , and monkeys [2, 15, 31–33].
Aldosterone stimulation of the MR may affect the cho-
roidal vascular system through various effects, such as
induction of oxidative stress, inflammation, hypertrophic
remodeling, fibrosis, and endothelial dysfunction [34,
35]. The two physiological ligands aldosterone and cor-
tisol are able to bind to the MR with similar affinity. In
epithelial tissues and the choroid, MR acts as a physio-
logical aldosterone receptor. It is protected from being
activated by glucocorticoids by the enzyme 11ß-hydroxy-
steroid dehydrogenase type 2, which metabolizes cortisol
into inactive cortisone [36]. Like the MR, this enzyme is
present in the choroid, RPE, and neurosensory retina
[31–33]. Without the conversion, MR acts as a cortisol
receptor, as blood levels of cortisol are much higher
compared to aldosterone levels, even when binding of
cortisol to corticosteroid binding globulin is taken into
account [37]. The effect of PA suggests ei ther
overactivation of aldosterone-preferring MRs or occupan-
cy of cortisol-preferring MRs, for example during pe-
riods in the circadian cycle when cortisol is normally
very low. In a rat model, MR overexpression increased
CT, and resulted in dilation of choroidal vessels, focal
disruption of RPE tight junctions, and RPE detachments
[2]. Preliminary clinical studies also indicate that
eplerenone and spironolactone have a beneficial effect
on CSC, although their exact role in the treatment of
CSC is somewhat controversial due to possible variable
and temporary treatment effects and a lack of random-
ized placebo-controlled trials [17–20]. Furthermore, there
does not seem to be a marked effect of these treatments
on CT [19]. Apart from a possible direct role of the MR
pathway in the pathogenesis of retinal abnormalities in
this PA patient cohort, effects of prolonged hypertension
(which was present in all patients) may have also played
a role. Moreover, MR antagonists were prescribed to
both patients in whom macular SRF was detected at the
moment of ophthalmological phenotyping. The relatively
severe PA in the patient group that received the ophthal-
mological phenotyping could also have contributed to the
results of this study [24].
In conclusion, findings suggestive of (subclinical) CSC
were detected in most patients with PA. Ophthalmologists
who treat CSC patients with hypertension of unknown
origin should thus have a high index of suspicion for
PA, in particular because of the underestimated incidence
of PA. In dealing with PA patients, clinicians also need to
be aware of the potential coexistence of CSC, which may
remain subclinical.
Fig. 2 Ophthalmological imaging of five patients with primary
hyperaldosteronism in whom retinal pigment epithelium (RPE)
c h a n g e s s u g g e s t i v e o f s u b c l i n i c a l c e n t r a l s e r o u s
chorioretinopathy (CSC) were detected at screening. a–d.
Extrafoveal optical coherence tomography (OCT) scanning of
the right (a) and the left eye (b) of this 72-year-old male patient
revealed mild outer retinal changes. Mild diffuse macular
hyperfluorescent changes were detected on fluorescein angiogra-
phy (FA) of the right (c) and the left eye (d). e–h. On the
foveal OCT scan of this 50-year-old male patient, subtle outer
retinal changes were found in the right eye (e), with a normal
OCT in the left eye (f). FA of the right eye (g) showed diffuse
hyperfluorescent changes, and a mild hyperfluorescence in the
macula of the left eye (h). i–l. Extrafoveal OCT scan of the
right eye (i) of a 59-year-old male patient revealed mild
hyperreflective focal irregularities on the photoreceptor/RPE lev-
el. On the foveal OCT scan of the left eye (j) intraretinal edema
was observed. FA of the right eye (k) of this patient showed
multifocal irregular hyperfluorescent changes, with some
peripapillary indistinct focal hyperfluorescent areas suggestive
of small leaking hot spots, despite an absence of serous SRF
on OCT. FA of the left eye (l) showed scars of previous scatter
laser treatments performed elsewhere for a retinal venous occlu-
sion. m–p. OCT scan (m) and FA of the right eye (o) of this
36-year-old female patient revealed no abnormalities. OCT scan-
ning of the area superior to the macula of the left eye (n)
revealed mild outer retinal changes, with corresponding mildly
hyperfluorescent changes on FA (p; arrowhead in n and p). q-t.
OCT scan (q) and FA of the right eye (r) of a 58-year-old male
patient showed no abnormalities. Foveal OCT scanning of the
left eye (s) revealed a small RPE detachment, with correspond-
ing mildly hyperfluorescent changes on FA (t; arrowhead in s
and t)
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